

# e-Therapeutics PLC

04:26 29 Sep 2015

## E-Therapeutics eyes full control of discovery platform tech

Drug developer E-Therapeutics (LON:ETX) is mulling taking full control of the technology behind in its drug discovery platform.

E-Therapeutics, which ended its latest half year with cash of more than £30m, said the value of any such acquisition would not exceed £2.5m with a possible share element.

The discovery platform currently has 10 live projects, which will be whittled down for formal pre-clinical development early next year, with the most promising to enter clinical development in 2017.

The other live discovery activities include hundreds of potential compounds, mostly in immuno-oncology.

Last month, the group detailed progress with two drugs currently on trial.

Results from a phase IIb trial of ETS6103 for depressive disorders are expected by the end of January, while ETS2101 has entered phase Ib trials for hepatocellular carcinoma and pancreatic cancer.

Interim losses to June were £5.8m (£5.1m) reflecting increased spending in both discovery and development arms offset slightly by lower administrative costs.

Spending is set to rise in the current half year as E-Therapeutics' projects progress.

**Price:** 14.375

**Market Cap:** £60.24 m

### 1 Year Share Price Graph



October 2019    April 2020    October 2020

### Share Information

**Code:** ETX

**Listing:** AIM

|                |             |            |
|----------------|-------------|------------|
| <b>52 week</b> | <b>High</b> | <b>Low</b> |
|                | 23          | 1.25       |

**Sector:** Pharma & Biotech

**Website:** [www.etherapeutics.co.uk](http://www.etherapeutics.co.uk)

### Company Synopsis:

*We are an Oxford, UK-based business with a revolutionary computer-based platform and a unique network-driven drug discovery ("NDD") methodology which allows us to discover novel and better drugs faster.*

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).